The trial, sponsored by Roswell Park Cancer Institute, is currently recruiting patients to evaluate the efficacy of lamivudine in combination with standard chemoimmunotherapy for extensive stage SCLC. Given the high unmet medical need in this indication, particularly due to the rapid development of treatment resistance, successful outcomes could position lamivudine as a valuable adjunct therapy, potentially expanding its market presence beyond antiviral applications. The competitive landscape includes existing chemotherapy and immunotherapy options, with lamivudine offering a novel mechanism to combat resistance. Stakeholders should monitor the trial's progress and outcomes closely, as positive results could lead to strategic partnerships or licensing opportunities.